Список литературы

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009; 113(11): 2386 - 93. DOI: 10.1182/blood-2008-07-162503.

2. Cines D.B., Bussel J.B., Liebman H.A., et al. The ITP syndrome: Pathogenic and clinical diversity. Blood. 2009; 113(26): 6511 - 21. DOI: 10.1182/blood-2009-01-129155.

3. Audia S., M., Samson M., et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6): 620 - 32. DOI: 10.1016/j.autrev.2017.04.012.

4. McMillan R. Antiplatelet Antibodies in Chronic Adult Immune Thrombocytopenic Purpura: Assays and Epitopes. In: Journal of Pediatric Hematology/Oncology. J Pediatr Hematol Oncol; 2003. DOI: 10.1097/00043426-200312001-00013.

5. Fischer P., Jendreyko N., Hoffmann M., et al. Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. Br J Haematol. 1999; 105(3): 626 - 40. DOI: 10.1046/j.1365-2141.1999.01407.x.

6. Kuwana M., Kaburaki J., Kitasato H., et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001; 98(1): 130 - 9. DOI: 10.1182/blood.V98.1.130.

7. Consolini R., Legitimo A., Caparello M.C. The centenary of immune thrombocytopenia - Part 1: Revising nomenclature and pathogenesis [Internet]. Vol. 4, Frontiers in Pediatrics. Front Pediatr; 2016. DOI: 10.3389/fped.2016.00102.

8. Zufferey A., Kapur R., Semple J. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med. 2017; 6(2): 16. DOI: 10.3390/jcm6020016.

9. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia [Internet]. Vol. 43, Presse Medicale. Presse Med; 2014. DOI: 10.1016/j.lpm.2014.01.010.

10. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program. 2012; 2012: 306 - 12. DOI: 10.1182/asheducation.v2012.1.306.3798320.

11. Lakshmanan S., Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost. 2012; 10(10): 1988 - 98. DOI: 10.1111/j.1538-7836.2012.04876.x.

12. Journeycake J.M. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. [Internet]. Vol. 2012, Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. Hematology Am Soc Hematol Educ Program; 2012. p. 444 - 9. DOI: 10.1182/asheducation.v2012.1.444.3806864.

13. Neunert C., Lim W., Crowther M., et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190 - 207. DOI: 10.1182/BLOOD-2010-08-302984.

14. Consolini R., Costagliola G., Spatafora D. The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach. Front Pediatr. 2017; 5: 179. DOI: 10.3389/FPED.2017.00179.

15. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168 - 86. DOI: 10.1182/blood-2009-06-225565.

16. Provan D., Arnold D.M., Bussel J.B., et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22): 3780 - 817. DOI: 10.1182/bloodadvances.2019000812.

17. T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie. 2017; 37(1): 36 - 44. DOI: 10.5482/HAMO-16-06-0017.

18. Matzdorff A., Meyer O., Ostermann H., et al. Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, , SGH, GPOH, and DGTI. Oncol Res Treat. 2018; 41 (Suppl. 5): 1 - 30. DOI: 10.1159/000492187.

19. Bleesing JJH, Nagaraj CB, Zhang K. Autoimmune Lymphoproliferative Syndrome. 2006 Sep 14 [updated 2017 Aug 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2024. PMID: 20301287.

20. E, Affenberger S, Zimmer J, Vinzio S, Grosu D, Pistol G, Maloisel F, Weitten T, Kaltenbach G, JF. Current hematological findings in cobalamin deficiency. A study of 201 consecutive patients with documented cobalamin deficiency. Clin Lab Haematol. 2006 Feb; 28(1): 50 - 6. doi: 10.1111/j.1365-2257.2006.00755.x.

21. Arnold D.M. Bleeding complications in immune thrombocytopenia. Hematol (United States). 2015; 2015(1): 237 - 42. DOI: 10.1182/asheducation-2015.1.237.

22. Iyori H., Bessho F., Ookawa H., et al. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol. 2000; 79(12): 691 - 5. DOI: 10.1007/s002770000219.

23. Butros L.J., Bussel J.B. Intracranial hemorrhage in immune thrombocytopenic purpura: A retrospective analysis. J Pediatr Hematol Oncol. 2003; 25(8): 660 - 4. DOI: 10.1097/00043426-200308000-00017.

24. Blanchette V., Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management//Pediatric clinics of North America. - 2008. - Т. 55. - N. 2. - С. 393 - 420

25. Bansal D, Rajendran A, Singhi S. Newly diagnosed immune thrombocytopenia: update on diagnosis and management. Indian J Pediatr. 2014 Oct; 81(10): 1033 - 41. doi: 10.1007/s12098-013-1217-2.

26. Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID. Blood. 2022 Aug 11; 140(6): 542 - 555. doi: 10.1182/blood.2020006480.

27. Labrosse R, Vincent M, Nguyen UP, Chartrand C, Di Liddo L, Pastore Y. Using a standardised protocol was effective in reducing hospitalisation and treatment use in children with newly diagnosed immune thrombocytopenia. Acta Paediatr. 2017 Oct; 106(10): 1617 - 1623. doi: 10.1111/apa.13859.

28. Jang JH, Kim JY, Mun YC, Bang SM, Lim YJ, Shin DY, Choi YB, Yhim HY, Lee JW, Kook H; on the behalf of Korean Aplastic Anemia Working Party. Management of immune thrombocytopenia: Korean experts recommendation in 2017. Blood Res. 2017 Dec; 52(4): 254 - 263. doi: 10.5045/br.2017.52.4.254.

29. Rodeghiero F., Ruggeri M. ITP and international guidelines: What do we know, what do we need? Press Medicale. 2014; 43(4P2). DOI: 10.1016/J.LPM.2014.02.004.

30. Ramaswamy K., Hsieh L., Leven E., et al. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr. 2014; 165(3). DOI: 10.1016/j.jpeds.2014.03.060.

31. Tarantino M.D., Bussel J.B., Blanchette V.S., et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10039): 45 - 54. DOI: 10.1016/S0140-6736(16)00279-8.

32. Bussel J.B., Buchanan G.R., Nugent D.J., et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011; 118(1): 28 - 36. DOI: 10.1182/blood-2010-10-313908.

33. Bussel J.B., Hsieh L., Buchanan G.R., et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015; 62(2): 208 - 13. DOI: 10.1002/pbc.25136.

34. Bussel J.B., de Miguel P.G., Despotovic J.M., et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015; 2(8): e315 - 25. DOI: 10.1016/S2352-3026(15)00114-3.

35. Grainger J.D., Locatelli F., Chotsampancharoen T., et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet (London, England). 2015; 386(10004): 1649 - 58. DOI: 10.1016/S0140-6736(15)61107-2.

36. Neunert C., Despotovic J., Haley K., et al. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016; 63(8): 1407 - 13. DOI: 10.1002/PBC.26003.

37. Kuter D.J., Macahilig C., Grotzinger K.M., et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015; 101(3): 255 - 63. DOI: 10.1007/S12185-014-1731-7.

38. Scaramucci L., Giovannini M., Niscola P., et al. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus. 2014; 12(4): 605. DOI: 10.2450/2014.0246.13.

39. Nakazato T., Ito C., Mihara A., et al. Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim. Int J Hematol 2012 972. 2012; 97(2): 291 - 3. DOI: 10.1007/S12185-012-1253-0.

40. Piccin A., Amaddii G., Natolino F., et al. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus. 2014; 12 (Suppl 1): s149. DOI: 10.2450/2013.0289-12.

41. Sartori R., Candiotto L., Ruggeri M., et al. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim. Blood Transfus. 2014; 12 Suppl 1 (Suppl 1). DOI: 10.2450/2013.0135-13.

42. D'Arena G., Guariglia R., Mansueto G., et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood. 2013; 121(7): 1240 - 2. DOI: 10.1182/BLOOD-2012-11-465575.

43. Khellaf M., Viallard J.F., Hamidou M., et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013; 98(6): 881 - 7. DOI: 10.3324/HAEMATOL.2012.074633.

44. Suntsova E.V., Maschan A.A., Baydildina D.D., et al. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center. Pediatr Blood Cancer. 2019; 66(6): e27704. DOI: 10.1002/PBC.27704.

45. Bussel J.B., Lee C.S., Seery C., et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014; 99(7): 1264 - 71. DOI: 10.3324/HAEMATOL.2013.103291.

46. Abdelwahab OA, Mechi A, Gahlan S, Hamadein FE, Kadhim H, Ismail D, Soliman Y, El-Samahy M. Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis. Clin Rheumatol. 2024 Feb; 43(2): 621 - 632. doi: 10.1007/s10067-023-06820-4.

47. Berrueco R, E, Deya-Martinez A, Solsona M, A, J, Yiyi L, Vlagea A, Ruiz-Llobet A, Alsina L. Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity. Front Pediatr. 2023 Oct 17; 11:1 174671. doi: 10.3389/fped.2023.

48. Mashhadi M.A. et al. Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia//DARU Journal of Pharmaceutical Sciences. - 2012. - Т. 20. - С. 1 - 5.

49. Aljebab F., Choonara I., Conroy S. Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children. PLoS One. 2017; 12(1): e0170259. DOI: 10.1371/JOURNAL.PONE.0170259.

50. Bickler S.W., Harrison M.W., Campbell J.R. Perforated peptic ulcer disease in children: association of corticosteroid therapy//Journal of pediatric surgery. - 1993. - Т. 28. - N. 6. - С. 785 - 787.

51. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials//The Lancet Gastroenterology & Hepatology. - 2018. - Т. 3. - N. 4. - С. 231 - 241.

52. Harapan Parlindungan R. THE ROLE OF METHYLPREDNISOLONE IN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA: A CASE REPORT.

53. Celik M. et al. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura//Journal of thrombosis and thrombolysis. - 2013. - Т. 35. - С. 228 - 233.